TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22182667
Drug: Family-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused treatment for prodromal youth (6-month, 18-session intervention)
Study: 21510531
Drug: Buffy coat
Normalized name: Leucocyte buffy coat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffy coat (mesenchymal stem cell concentrate) injection along with arthroscopic debridement
Study: 16135173
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (200 mg in 200 mL saline) for 2 hours
Study: 16135173
Drug: Saline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (200 mL)
Study: 12424551
Drug: Stimulant medications
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medications (6-month trial)
Study: 15960563
Drug: Sertraline (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-100 mg/day)
Study: 8477412
Drug: Fluoxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-40 mg/day)
Study: 6786953
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg copper daily (fixed dose)
Study: 6786953
Drug: Copper requirements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper requirements for total parenteral nutrition
Study: 6786953
Drug: Copper requirements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper requirements for total parenteral nutrition with diarrhea or increased fluid loss
Study: 6786953
Drug: Urinary copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary copper excretion
Study: 31636000
Drug: 2D Gaussian
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2D Gaussian probability density function of rectal motion and wall thickness (2D pdfM&TW)
Study: 31636000
Drug: Probability density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probability density functions of rectal deformation (DW), rectal dose distribution (RM), and changes in rectal wall thickness (TW)
Study: 31636000
Drug: Gaussian mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaussian mixture distributions for rectal wall thickness
Study: 26527863
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of dicloxacillin sodium (0.25, 0.5, 1.0, and 2.0 g)
Study: 26527863
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of dicloxacillin sodium (0.25 or 0.5 g every 6 hours for 3 days)
Study: 11132503
Drug: Wand injections
Normalized name: CLEANSER,PROSTHETIC THE LINER WAND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wand injections
Study: 11132503
Drug: Traditional palatal
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional palatal injection
Study: 20855349
Drug: Psilocybin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (high doses)
Study: 17209189
Drug: Weekly multiple-micronutrient
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multiple-micronutrient foodLET providing twice the RNI (WMM)
Study: 17209189
Drug: Daily 10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 10-mg Fe foodLET (DI)
Study: 11531839
Drug: Calcipotriol 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 0.05 mg g(‐1) cream applied 1 hour before PUVA treatment
Study: 11531839
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied 1 hour before PUVA treatment
Study: 16412037
Drug: Regional interventional
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional interventional chemotherapy (infused directly into the common hepatic artery)
Study: 16412037
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (via peripheral vein)
Study: 8216438
Drug: LNC‐834 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNC‐834 (350 mg of hydrated salt corresponding to 226 mg anhydrous free base each) administered twice daily for 9 days, with warfarin (0.36 +/- 0.03 mg/kg) on the 4th day
Study: 27299458
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of Life Assessment based on Traditional Chinese Medicine (QLASTCM‐Ga)
Study: 24072699
Drug: Resveratrol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (1000 mg daily for week 1 followed by 2000 mg daily for week 2)
Study: 20495134
Drug: ABT-107 single
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-107 single oral doses (1, 3, 10, 30, 60, 80, and 100 mg)
Study: 20495134
Drug: ABT-107 20-mg
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-107 20-mg single dose (effect of food)
Study: 19054806
Drug: Sequential Organ
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Organ Failure Assessment score
Study: 29231568
Drug: Drug-spreading moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-spreading moxibustion
Study: 29231568
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg once a day for three days)
Study: 15355747
Drug: COX-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 inhibitors
Study: 17923032
Drug: Selective COX-2
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective COX-2 inhibitors
Study: 22442673
Drug: Standard decentralised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard decentralised psychiatric treatment
Study: 20136164
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid + moderate-dose statin
Study: 18376348
Drug: Metoprolol (0.5-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.5-1.5 mg/kg/d)
Study: 16045525
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (600 microg, followed by 400 microg)
Study: 12477581
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg IV (Group D)
Study: 12477581
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol 1.25 mg IV and ondansetron 4 mg IV (Group D+O)
Study: 12477581
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (Combination of droperidol and ondansetron)
Study: 7135113
Drug: Caffeine solution
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine solution (5 mg caffeine/kg body weight) ingested 1 hour prior to running
Study: 27723261
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy (MBT) in addition to usual treatment
Study: 19750959
Drug: Individualized physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized physical rehabilitation (IPR) consisting of four physical therapy sessions plus three telephone calls
Study: 24954156
Drug: Antidepressant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatments
Study: 9521955
Drug: AMOX/CLAV (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMOX/CLAV (40 mg/kg in 3 divided doses daily)
Study: 8041534
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (continuous conjugated equine estrogens at 0.625 mg/day with sequential dl-norgestrel at 0.15 mg/day for 12 days each cycle)
Study: 8041534
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy (patches delivering continuous 17 beta-estradiol at 0.05 mg/day with sequential norethindrone acetate at 0.25 mg/day for 14 days each cycle)
Study: 30641096
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment continued after meeting switching criteria at month 3
Study: 30641096
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment continued after meeting switching criteria at month 6
Study: 23062021
Drug: Yoga group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga group (50-60 minutes of yogic practices daily for 42 days)
Study: 11475562
Drug: Salbutamol (Steri-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (Steri-Neb Salamol 2.5 mg) nebulization
Study: 31713297
Drug: Topical tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tamoxifen gel
Study: 31713297
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen 10 mg OD
Study: 28366818
Drug: Adjunctive photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive photodynamic therapy (PDT)
Study: 23560645
Drug: Adjunctive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive local drug delivery (LDD) with minocycline microspheres
Study: 22077420
Drug: Iseganan HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Iseganan (DB16010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iseganan HCl 9 mg/3 ml, administered as a swish and swallow solution, six times daily for 21-28 days.
Study: 20384753
Drug: KTP laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP laser treatment
Study: 16020212
Drug: IPL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL treatment
Study: 15780536
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg estradiol and 0.125 mg norethisterone acetate daily
Study: 11808971
Drug: parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib sodium 40 mg b.i.d. for 7 days
Study: 11808971
Drug: ketorolac 15
Normalized name: ketorolac 15.75 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 15 mg q.i.d. for 5 days
Study: 6967580
Drug: Rifampin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (20 mg/kg for four days)
Study: 6967580
Drug: Rifampin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (20 mg/kg for four days) after ampicillin treatment failure
Study: 28855078
Drug: Guided de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided de-escalation group (1 week prasugrel followed by 1 week clopidogrel and PFT-guided maintenance therapy)
Study: 25877813
Drug: carnitine‐orotate complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: carnitine‐orotate complex (824 mg, three times daily)
Study: 16398425
Drug: Pingxiao capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pingxiao capsule (PXC) plus endocrinotherapy (ET)
Study: 12188940
Drug: High-dose mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mannitol (approximately 1.4 g/kg)
Study: 12188940
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose mannitol (approximately 0.7 g/kg)
Study: 345433
Drug: Heparin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin added to dialysis solution
Study: 345433
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin added to dialysis solution
Study: 22023022
Drug: Concurrent alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent alcohol and smoking treatment
Study: 17688969
Drug: docetaxel/gemcitabine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel/gemcitabine combination therapy
Study: 11507733
Drug: Prostane (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostane (herbal formulation) at a dose of two tablets a day for 1 year
Study: 11507733
Drug: Prostane (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostane (herbal formulation)
Study: 7851270
Drug: IDDM patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDDM patients with altered urinary albumin excretion rate (AER > or = 20 micrograms/min)
Study: 12648191
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) remifentanil (0.13 microg kg‐1 x min‐1)
Study: 12648191
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) remifentanil (0.39 microg kg‐1 x min‐1)
Study: 16114784
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg t.i.d.
Study: 3534852
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg t.i.d.
Study: 10517426
Drug: Oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oseltamivir (100 mg once daily, 100 mg twice daily)
Study: 25043337
Drug: RBP-7000 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-7000 at 60 mg and 90 mg
Study: 22932339
Drug: GSK1034702 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1034702 (8 mg)
Study: 17598697
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation tablets
Study: 17598697
Drug: Melcam 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melcam 15 mg tablets (test preparation)
Study: 23571785
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide cream (TA)
Study: 14524485
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (354 ml/day)
Study: 14524485
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice (354 ml/day)
Study: 1410946
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment (manipulation, specific mobilization, muscle stretching, auto-traction, cortisone injections)
Study: 2412056
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of Ketanserin.
Study: 29576307
Drug: MenACWY-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT vaccine (1 and 2 doses)
Study: 29576307
Drug: MenACWY-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT vaccine (2 doses)
Study: 22438232
Drug: Ciclesonide (507
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (507 μg/d)
Study: 22438232
Drug: Control (202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (202 μg/d)
Study: 18671773
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone and intranasal budesonide for 2 weeks, plus intranasal budesonide for 10 additional weeks
Study: 12477601
Drug: THC 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 0.15 mg/min
Study: 12477601
Drug: THC 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 0.25 mg/min
Study: 12477601
Drug: THC (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (high dose)
Study: 7776110
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of synthetic surfactant
Study: 7776110
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of synthetic surfactant
Study: 6986110
Drug: Inhalant solution
Normalized name: watermelon allergenic extract 0.1 GM/ML Inhalant Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalant solution of metaproterenol
Study: 6986110
Drug: 0.5% solution
Normalized name: VueBlu 0.5% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% solution of isoproterenol
Study: 20876217
Drug: SBIRT (Screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT (Screening, Brief Intervention and Referral for Treatment)
Study: 12694346
Drug: Cholesterol-lowering therapy
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering therapy with simvastatin and ezetimide
Study: 8612386
Drug: Iron-gluconate formulation
Normalized name: IRON (AS FERROUS GLUCONATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-gluconate formulation
Study: 1992306
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (n = 7; maximal dose, 30 mg/kg/day)
Study: 1992306
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (n = 10; dose range, 2.5 to 12 g/day)
Study: 25985806
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 43 mg
Study: 23357834
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 86 mg
Study: 25985806
Drug: Morphine IR
Normalized name: Morphine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine IR 30 mg
Study: 25985806
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 75-100 mg
Study: 25985806
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 125-175 mg
Study: 25985806
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR 20 mg
Study: 26437499
Drug: Control (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5% hydroalcohol solution)
Study: 17323183
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Etidronate (200 mg daily)
Study: 17323183
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (1 microg alfacalcidol daily)
Study: 10947691
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl and midazolam
Study: 1631861
Drug: Creatine phosphate
Normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine phosphate (10 mmol/L)
Study: 26003434
Drug: Transdiagnostic Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic Behavior Therapy (TBT)
Study: 21988544
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Treatment for Depression (BATD)
Study: 30203777
Drug: Radix astragali
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix astragali and Salvia miltiorrhiza injection
Study: 18452346
Drug: Olanzapine LAI
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine LAI 210 mg/2 weeks
Study: 12844377
Drug: Retinyl palmitate-containing
Normalized name: RETINYL PALMITATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate-containing toothpaste (1 mg/g)
Study: 8850403
Drug: Intravenous propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone, 1 to 2 mg/kg in a 10‐minute bolus, followed by an infusion of 420 mg in 24 hours.
Study: 8850403
Drug: Intravenous amiodarone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone, 2.5 to 5 mg/kg in a 10‐minute bolus followed by an infusion of 900 mg in 24 hours.
Study: 3914368
Drug: Desoximetasone ointment
Normalized name: Desoximetasone Ointment
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoximetasone ointment 0.25%
Study: 27671673
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) implant
Study: 11561938
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/day
Study: 29063516
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg every 12 h
Study: 26831173
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine administered extradurally
Study: 26831173
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine administered via femoral and transgluteal sciatic electrolocation-guided nerve block
Study: 25439693
Drug: Adjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant capecitabine plus oxaliplatin (8 cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1 for 6 months)
Study: 20581162
Drug: Oropharyngeal cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal cavity spray of benzydamine hydrochloride (BH) and distilled water on the ET cuff (Group A)
Study: 20581162
Drug: Both oropharyngeal
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oropharyngeal cavity and ET cuff received BH spray (Group B)
Study: 3535474
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg orally twice a day (or 400 mg if weight > 80 kg) from 36 hours after surgery until discharge (usually on the seventh day)
Study: 3535474
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beta-blocking drugs)
Study: 29044968
Drug: DUT‐TAM FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DUT‐TAM FDC therapy (dutasteride 0.5 mg and tamsulosin 0.4 mg)
Study: 22616853
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of controlled-release melatonin and cognitive-behavioural therapy
Study: 22616853
Drug: Controlled-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release melatonin